List of Biologics Companies in Poland - 8

Adamed Pharma is a Polish pharmaceutical and biotechnology company that was established thanks to its own scientific thought and its own patents. Currently, it produces approximately 500 products offered to patients in 78 countries around the world. It has representative offices in Spain, Russia, the Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan, Slovakia and Ukraine. It currently employs approximately 2,400 people. The company has been conducting its own innovative research and development activities for over 20 years. It cooperates with leading universities and research institutes in Poland and abroad. The company's intellectual property is protected by over 200 patents in most countries around the world. Adamed also owns a controlling stake in Dat Vi Phu, one of the fastest growing local pharmaceutical companies in Vietnam. This transaction was the largest direct Polish investment in Vietnam so far. In 2019, Adamed acquired a block of shares in the Italian company Ecupharma, operating in the field of neuropsychiatry and urology.

At Cellis, we are at the forefront of cell-based oncology therapy, specializing in innovative solutions for the treatment of solid tumors. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC), which leverages the revolutionary TRAIN mechanism. This biologic discovery enables the efficient and highly targeted delivery of active compounds directly into the cytoplasm of cancer cells, leading to cell death and tumor shrinkage. MDC also reshapes the tumor microenvironment, fostering immune resistance to cancer growth. Our intellectual property is protected through PCT patent applications, with additional filings pending. As we prepare for first-in-human clinical trials in Q2 2025, we continue to push the boundaries of cancer treatment through integrated therapeutic and diagnostic solutions.

Our mission is to deliver mRNA technology innovations to revolutionize future therapies and the prevention of many diseases. We invent, develop, manufacture and apply our solutions for the benefit of pharmaceutical partners, and to improve people’s lives. With passion, ExploRNA Therapeutics develops ground-breaking innovations of mRNA as a therapeutic platform, applies those solutions in unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical partners.

IBSS BIOMED S.A. – an expert in vaccines and probiotics – is a Polish biotechnology company operating continuously since 1945. We make exceptional products, which are the effects of the synergy of our experience and the knowledge of reputable research institutes and modern technologies. For over 65 years, we have enjoyed the trust of patients, physicians and business partners. The basis of IBSS BIOMED S.A.'s activity is the production of: probiotics, vaccines (also those included in the Preventive Immunization Schedule), dietary supplements, allergens, as well as diagnostic preparations, media and indicators. We are known for innovative solutions and inventive ideas, which allow us to maintain the highest quality of the manufactured products and, as a result, satisfy customers' expectations. The company constantly improves its products so that they meet quality and market requirements, and are compliant with the highest standards of modern pharmaceutics by: introducing new manufacturing technologies, research methods, modernising the equipment of our laboratories. The areas of the company's activity: Production (own, contract manufacturing and research) R&D of the company's own products (clinical trials, registration) Sales and marketing Export/import

JJP Biologics is an innovative Polish biotechnology company developing novel biological therapies around established companion diagnostics. Our range of programs are in early stage development and we are actively seeking to cooperate with investors and academics on new or existing projects.

Mabion S.A. is a Polish biopharmaceutical CDMO providing extensive drug development and biomanufacturing services to pharmaceutical and Biotech companies globally. We offer services for clinical and commercial manufacture of recombinant protein therapeutics, including process and analytical development services, GMP manufacture of Drug Substance (from small scale up to 4 x 2.000 liter single-use bioreactor sizes), GMP manufacture of Drug Product in our state-of-the-art filling line and an extensive set of analytics and QC tests. This is supported by a robust quality assurance and regulatory affairs department. In addition to our regular CDMO offering, Mabion also took part in the global fight against the coronavirus pandemic by signing a record contract with Novavax Inc. in October 2021 for the commercial production of the antigen for their COVID-19 vaccine. This partnership has proven to be very successful, leading to several subsequent additional services offered by Mabion, augmenting the main commercial-scale manufacturing contract. We aim to establish ourselves as a key global player in the global contract manufacturing and contract drug development market offering a broad range of high-quality integrated services to the Biotech and pharmaceutical market. Mabion is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers. Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterisation of antibodies and aptamers, as well as protein production, purification and analysis.